Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis (PRINTOJDMTR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00323960
Recruitment Status : Completed
First Posted : May 10, 2006
Results First Posted : March 16, 2021
Last Update Posted : March 16, 2021
Sponsor:
Collaborator:
Pediatric Rheumatology International Trials Organization
Information provided by (Responsible Party):
Nicolino Ruperto, MD, MPH, Istituto Giannina Gaslini

Brief Summary:
This is a 5-year project, involving 185 partners from 46 countries ((110 in 21 European Union (EU) States and 75 in 25 extra-EU States)), with a randomised clinical trials (RCT) in juvenile dermatomyositis (JDM): 5-year phase III single-blind, RCT in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus Cyclosporine A. The trial is aimed to find out the treatment regimen associated with the lowest occurrence of flare and the lowest drug related toxicity

Condition or disease Intervention/treatment Phase
Juvenile Dermatomyositis Drug: 3 MPDN pulse + PDN Drug: 3 MPDN pulse + PDN + CSA Drug: 3 MPDN pulse + PDN + MTX Phase 3

Detailed Description:

Scientific objectives: The proposed project is aimed to improve treatment approaches for rare, severe and disabling paediatric rheumatic diseases (PRD). This goal will be achieved by the Paediatric Rheumatology International Trials Organisation (PRINTO) an international network whose main function is to provide a scientific base for current PRD treatments for which no evidence based data exist in the literature, and for drugs for which there is no support from industries.

This is a 5-year project, involving 46 countries (110 in 21 EU States and 75 in 25 extra-EU States), with a randomised clinical trials (RCT) in juvenile dermatomyositis (JDM): 5-year phase III single-blind, RCT in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus Cyclosporine A (CsA). The trial is aimed to find out the treatment regimen associated with the lowest occurrence of flare and the lowest drug related toxicity. The retention on treatment will be used as main measure of effectiveness.

Methodology: The present protocol is the natural follow up of previous work conducted by PRINTO. In particular the RCT foreseen in this protocol is modelled after the successful completion of an early phase trial with MTX in juvenile idiopathic arthritis, and will use validated JDM outcome measures for the evaluation of response to therapy.

It is the basic premise of this protocol that, without i) the involvement of the international paediatric rheumatology community, ii) the innovative type of mechanism described herein, these studies would never be conducted.

Objectives. The goals of the current protocol is therefore the natural follow-up of the objectives achieved with the previous grants and, in particular, of projects designed to discern new models for the successful conduct of clinical trials in children with rare diseases, and to develop standardized and validated measures for the evaluation of response to therapy in JDM.

The proposed trial in JDM (prednisone [PDN] versus PDN plus methotrexate [MTX] versus PDN plus cyclosporine [CsA]), should serve as a model for the successful running of early phase clinical trials for severe and disabling rare diseases of childhood.

The ultimate aim of these trials is to provide evidence-based information about the clinical utility of drugs in the management of rare paediatric conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate
Actual Study Start Date : May 31, 2006
Actual Primary Completion Date : May 12, 2011
Actual Study Completion Date : November 29, 2015


Arm Intervention/treatment
Active Comparator: Methylprednisolone pulse (MPDN)+PDN+CSA
MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
Drug: 3 MPDN pulse + PDN + CSA
3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses

Active Comparator: MPDN+PDN+MTX
MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
Drug: 3 MPDN pulse + PDN + MTX
3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.

Active Comparator: MPDN+PDN
MPDN= methylprednisolone PDN= prednisone or equivalent
Drug: 3 MPDN pulse + PDN
3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.




Primary Outcome Measures :
  1. Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by > 30%. [ Time Frame: 6 months ]

    The PRINTO Juvenile Dermatomyositis (JDM) core set variables are:

    1. muscle strength by the mean of the Childhood Myositis Assessment Scale (CMAS);
    2. physician's global assessment of disease activity on a 10 cm Visual Analogue Scale (VAS);
    3. global disease activity assessment by the mean of the Disease Activity Index (DAS);
    4. parent's/patient's global assessment of overall well-being on a 10 cm VAS;
    5. functional ability assessment by the mean of the Childhood Health Assessment Questionnaire (CHAQ)
    6. health-related quality of life assessment.

  2. Time to Clinical Remission [ Time Frame: 60 months ]
    Clinical remission is defined as the status of inactive disease for at least 6 continuous months defined as normal muscle strength (CMAS equal to 52) and physician global assessment of disease activity equal to 0.


Secondary Outcome Measures :
  1. Time to Major Therapeutic Changes [ Time Frame: 60 months ]
    Time to major therapeutic changes is defined as the addition of CSA or MTX or any other disease-modifying antirheumatic drug (DMARS) in any of the 3 groups or discontinuation of assigned therapy for any reason including adverse events. Retention on treatment was used as main measure of effectiveness.

  2. Time to Prednisone, or Equivalent, Discontinuation [ Time Frame: 60 months ]
    Prednisone or equivalent glucocorticoid discontinuation is defined as the complete discontinuation of glucocorticoids



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria. Each patient must meet all the following criteria in order to participate in this trial:

  1. Newly diagnosed and untreated children (only treatment with 1 NSAID is allowed and/or prednisone >1 mg/kg/day for no more than 1 month from diagnosis) with probable or definite diagnosis of JDM according to published (12;13). If a muscle biopsy will be performed (optional) it will be read by the pathologists of the participating centres (light and immunofluorescence). Slides of paraffin-embedded sections from all patients will be re-viewed by a blinded myopathologist at PRINTO.
  2. Age at enrolment ≤ 18 years.
  3. Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial, and then every 3 months. If sexually active, they must agree to use adequate contraception, throughout study participation, and must have no intention of conceiving during the course of the study. Post-pubertal males must have no plans to father a child during the study and agree to use adequate birth control methods if sexually active.
  4. Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate
  5. Duly executed, written, informed consent obtained from the parents/patient.

Exclusion Criteria. Any of the following will exclude a patient from this trial:

  1. Neutrophil count <1,500/mm3 and/or platelet count <50,000/mm3
  2. Demonstration of cutaneous or gastrointestinal ulceration of JDM related pulmonary disease or cardiomyopathy at the time of diagnosis.
  3. History of poor compliance.
  4. Evidence of current use of alcohol or illicit drugs abuse.
  5. Live vaccines not allowed during the entire duration of the trial.

Dropout Criteria. Patients will be considered "treatment failures", and dropped from the trial but included in efficacy analysis, if any of the following will occur during the active period of the trial.

  1. Non compliance with study medication administration
  2. Enrolment in other therapeutic trials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00323960


Locations
Layout table for location information
Italy
Istituto Giannina Gaslini
Genoa, Italy, 16147
Sponsors and Collaborators
Istituto Giannina Gaslini
Pediatric Rheumatology International Trials Organization
Investigators
Layout table for investigator information
Principal Investigator: Nicolino Ruperto, MD, MPH Istituto Giannina Gaslini _ PRINTO Senior Scientist
Study Chair: Alberto Martini, MD, Prof. Istituto Giannina Gaslini_PRINTO Chairman
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nicolino Ruperto, MD, MPH, Senior Scientist of PRINTO, Istituto Giannina Gaslini
ClinicalTrials.gov Identifier: NCT00323960    
Other Study ID Numbers: IGG-PRINTO-002
AIFA ( Other Grant/Funding Number: Agenzia Italiana del Farmaco (no FARMJWPZ) )
Myositis Association ( Other Grant/Funding Number: Myositis Association )
First Posted: May 10, 2006    Key Record Dates
Results First Posted: March 16, 2021
Last Update Posted: March 16, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be provided upon request to the Paediatric Rheumatology InterNational Trials Organisation (PRINTO) network as per its bylaws
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Time Frame: Data will be available upon request
Access Criteria: Request to the Paediatric Rheumatology International Trials Organisation (PRINTO) international coordinating centre: PRINTO@gaslini.org
URL: https://www.PRINTO.it/
Keywords provided by Nicolino Ruperto, MD, MPH, Istituto Giannina Gaslini:
Juvenile dermatomyositis
randomised actively controlled clinical trial
prednisone
cyclosporine
methotrexate
effectiveness
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatomyositis
Polymyositis
Myositis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases